Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -102.14% is 137% below its 2-year average of 275.32%, near the low end of its 2-year range (-126.74%–1634.29%).
As of the fiscal period ended Saturday, March 31, 2018. 33.88% below its 12-month average of -76.30%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2018 (2018-03-31): -102.14%.
EBITDA MARGIN
-102.14%
EBITDA MARGIN AVG TTM
-76.30%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-33.88%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$54.14M
EBITDA Margin
-2290.88%
TTM Avg
-3688.53%
3Y Avg
-3688.53%
5Y Avg
-3177.84%
Market Cap
$57.01M
EBITDA Margin
-89640.62%
TTM Avg
-44862.17%
3Y Avg
-44862.17%
5Y Avg
-44862.17%
Market Cap
$57.61M
EBITDA Margin
-48157.14%
TTM Avg
-48157.14%
3Y Avg
-25368.35%
5Y Avg
-13932.36%
Market Cap
$52.83M
EBITDA Margin
-40.55%
TTM Avg
-30.41%
3Y Avg
-34.23%
5Y Avg
-32.87%
Market Cap
$52.60M
EBITDA Margin
-36.35%
TTM Avg
-7.28%
3Y Avg
12.63%
5Y Avg
16.49%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aldeyra The (ALDX) | $55.25M | -102.14% | -76.30% | N/A | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.02M | N/A | N/A | N/A | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $54.14M | -2290.88% | -3688.53% | -3688.53% | -3177.84% |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $53.70M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.01M | -89640.62% | -44862.17% | -44862.17% | -44862.17% |
| Talphera, Inc. (TLPH)vs › | $57.61M | -48157.14% | -48157.14% | -25368.35% | -13932.36% |
| Spectral AI, Inc. (MDAI)vs › | $52.83M | -40.55% | -30.41% | -34.23% | -32.87% |
| Boundless Bio, Inc. (BOLD)vs › | $57.76M | N/A | N/A | N/A | N/A |
| Zhengye Biotechnology Holding Limited (ZYBT)vs › | $52.60M | -36.35% | -7.28% | 12.63% | 16.49% |
| Kalaris Therapeutics Inc (KLRS)vs › | $58.06M | -16170.91% | -8243.87% | -8243.87% | -8243.87% |
Gross Margin
0.0%
EBITDA Margin
-102.1%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2018-03-31 | -102.14% |
| 2017-12-31 | 0.00% |
| 2017-03-31 | -126.74% |
| 2016-12-31 | -28.82% |
| 2015-12-31 | 1634.29% |
